Clinical Trial Update: Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation

View source ↗

Summary

A clinical trial update evaluating whether zoledronic acid prevents bone loss after discontinuation of denosumab. The sponsor is the University of Calgary and t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteopenia
• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Denosumab (Prolia/Xgeva) (denosumab)
• Zoledronic acid (Reclast/Zometa) (zoledronic acid)

Snippet

Sponsor: University of Calgary | Conditions: Osteoporosis, Osteoporosis, Postmenopausal | Status: UNKNOWN